-
1
-
-
33745050401
-
Using positron emission tomography to facilitate CNS drug development
-
Lee, C.; Parde, L. Using positron emission tomography to facilitate CNS drug development Trends Pharmacol. Sci. 2006, 27, 310-317
-
(2006)
Trends Pharmacol. Sci.
, vol.27
, pp. 310-317
-
-
Lee, C.1
Parde, L.2
-
2
-
-
57649136969
-
The role of imaging in proof of concept for CNS drug discovery and development
-
Wong, D. F.; Tauscher, J.; Grunder, G. The role of imaging in proof of concept for CNS drug discovery and development Neuropsychopharmacology. 2009, 34, 187-203
-
(2009)
Neuropsychopharmacology.
, vol.34
, pp. 187-203
-
-
Wong, D.F.1
Tauscher, J.2
Grunder, G.3
-
3
-
-
38349095953
-
The role of molecular imaging in drug discovery and development
-
Hargreaves, R. J. The role of molecular imaging in drug discovery and development Clin. Pharmacol. Ther. 2008, 83, 349-353
-
(2008)
Clin. Pharmacol. Ther.
, vol.83
, pp. 349-353
-
-
Hargreaves, R.J.1
-
4
-
-
0033536020
-
Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A
-
DOI 10.1073/pnas.96.12.7071
-
Soderling, S.; Bayuga, S; Beavo, J. Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 7071-7076 (Pubitemid 29275011)
-
(1999)
Proceedings of the National Academy of Sciences of the United States of America
, vol.96
, Issue.12
, pp. 7071-7076
-
-
Soderling, S.H.1
Bayuga, S.J.2
Beavo, J.A.3
-
5
-
-
34447265905
-
Biochemistry and physiology of cyclic nucleotide phosphodiesterases: Essential components in cyclic nucleotide signaling
-
Conti, M.; Beavo, J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling Annu. Rev. Biochem. 2007, 76, 481-511
-
(2007)
Annu. Rev. Biochem.
, vol.76
, pp. 481-511
-
-
Conti, M.1
Beavo, J.2
-
6
-
-
54849409586
-
Distinct roles of PDE4 and PDE10A in the regulation of cAMP/PKA signaling in the striatum
-
Nishi, A.; Kuroiwa, M.; Miller, D. B.; O'Callaghan, J. P.; Bateup, H. S.; Shuto, T.; Sotogaku, N.; Fukuda, T.; Heintz, N.; Greengard, P.; Snyder, G. L. Distinct roles of PDE4 and PDE10A in the regulation of cAMP/PKA signaling in the striatum J. Neurosci. 2008, 28, 10460-10471
-
(2008)
J. Neurosci.
, vol.28
, pp. 10460-10471
-
-
Nishi, A.1
Kuroiwa, M.2
Miller, D.B.3
O'Callaghan, J.P.4
Bateup, H.S.5
Shuto, T.6
Sotogaku, N.7
Fukuda, T.8
Heintz, N.9
Greengard, P.10
Snyder, G.L.11
-
7
-
-
0042379865
-
Immunohistochemical localization of PDE10A in the rat brain
-
DOI 10.1016/S0006-8993(03)02754-9
-
Seeger, T. F.; Bartlett, B.; Coskran, T. M.; Culp, J. S.; James, L. C.; Krull, D. L.; Lanfear, J.; Ryan, A. M.; Schmidt, C. J.; Strick, C. A.; Varghese, A. H.; Williams, R. D.; Wylie, P. G.; Menniti, F. S. Immunohistochemical localization of PDE10A in the rat brain Brain Res. 2003, 985, 113-126 (Pubitemid 37088176)
-
(2003)
Brain Research
, vol.985
, Issue.2
, pp. 113-126
-
-
Seeger, T.F.1
Bartlett, B.2
Coskran, T.M.3
Culp, J.S.4
James, L.C.5
Krull, D.L.6
Lanfear, J.7
Ryan, A.M.8
Schmidt, C.J.9
Strick, C.A.10
Varghese, A.H.11
Williams, R.D.12
Wylie, P.G.13
Menniti, F.S.14
-
8
-
-
77956925425
-
Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues
-
Lakics, V.; Karran, E. H.; Boess, F. G. Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues Neuropharmacology 2010, 59, 367-374
-
(2010)
Neuropharmacology
, vol.59
, pp. 367-374
-
-
Lakics, V.1
Karran, E.H.2
Boess, F.G.3
-
9
-
-
33645893580
-
Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: Evidence for altered striatal function
-
DOI 10.1016/j.neuropharm.2006.01.012, PII S002839080600027X
-
Siuciak, J. A.; McCarthy, S. A.; Chapin, D. S.; Fujiwara, R. A.; James, L. C.; Williams, R. D.; Stock, J. L.; McNeish, J. D.; Strick, C. A.; Menniti, F. S.; Schmidt, C. J. Genetic deletion of the striatum-entriched phosphodiesterase PDE10A: evidence for altered strital function Neuropharmacology 2006, 51, 374-385 (Pubitemid 44061880)
-
(2006)
Neuropharmacology
, vol.51
, Issue.2
, pp. 374-385
-
-
Siuciak, J.A.1
McCarthy, S.A.2
Chapin, D.S.3
Fujiwara, R.A.4
James, L.C.5
Williams, R.D.6
Stock, J.L.7
McNeish, J.D.8
Strick, C.A.9
Menniti, F.S.10
Schmidt, C.J.11
-
10
-
-
38149121389
-
Behavioral characterization of mice deficient in the phosphodiesterase- 10A (PDE10A) enzyme on a C57/Bl6N congenic background
-
Siuciak, J.; McCarthy, S.; Chapin, D.; Martin, A.; Harms, J.; Schmidt, C. Behavioral characterization of mice deficient in the phosphodiesterase-10A (PDE10A) enzyme on a C57/Bl6N congenic background Neuropharmacology 2007, 54, 417-427
-
(2007)
Neuropharmacology
, vol.54
, pp. 417-427
-
-
Siuciak, J.1
McCarthy, S.2
Chapin, D.3
Martin, A.4
Harms, J.5
Schmidt, C.6
-
12
-
-
33847022578
-
The potential therapeutic use of phosphodiesterase 10 inhibitors
-
Kehler, J.; Ritzén, A.; Greve, D. The potential therapeutic use of phosphodiesterase 10 inhibitors Expert Opin. Ther. Pat. 2007, 17, 147-158
-
(2007)
Expert Opin. Ther. Pat.
, vol.17
, pp. 147-158
-
-
Kehler, J.1
Ritzén, A.2
Greve, D.3
-
13
-
-
70350445535
-
Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive and negative symptoms of schizophrenia
-
Grauer, S. M.; Pulito, V. L.; Navarra, R. L.; Kelly, M. P.; Kelley, C.; Graf, R.; Langen, B.; Logue, S.; Brennan, J.; Jiang, L.; Charych, E.; Egerland, U.; Liu, F.; Marquis, K. L.; Malamas, M.; Hage, T.; Comery, T. A.; Brandon, N. J. Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive and negative symptoms of schizophrenia J. Pharmacol. Exp. Ther. 2009, 331, 574-590
-
(2009)
J. Pharmacol. Exp. Ther.
, vol.331
, pp. 574-590
-
-
Grauer, S.M.1
Pulito, V.L.2
Navarra, R.L.3
Kelly, M.P.4
Kelley, C.5
Graf, R.6
Langen, B.7
Logue, S.8
Brennan, J.9
Jiang, L.10
Charych, E.11
Egerland, U.12
Liu, F.13
Marquis, K.L.14
Malamas, M.15
Hage, T.16
Comery, T.A.17
Brandon, N.J.18
-
14
-
-
69049103114
-
Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1 H -pyrazole-3-yl)-phenoxymethyl]quinoline (PF-2545920) for the treatment of schizophrenia
-
Verhoest, P. R.; Chapin, D. S.; Corman, M.; Fonseca, K.; Harms, J. F.; Hou, X.; Marr, E. S.; Menniti, F. S.; Nelson, F.; O'Connor, R.; Pandit, J.; Proulx-LaFrance, C.; Schmidt, A. W.; Schmidt, C. J.; Suiciak, J. A.; Liras, S. Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1 H -pyrazole-3-yl)-phenoxymethyl]quinoline (PF-2545920) for the treatment of schizophrenia J. Med. Chem. 2009, 52, 5188-5196
-
(2009)
J. Med. Chem.
, vol.52
, pp. 5188-5196
-
-
Verhoest, P.R.1
Chapin, D.S.2
Corman, M.3
Fonseca, K.4
Harms, J.F.5
Hou, X.6
Marr, E.S.7
Menniti, F.S.8
Nelson, F.9
O'Connor, R.10
Pandit, J.11
Proulx-Lafrance, C.12
Schmidt, A.W.13
Schmidt, C.J.14
Suiciak, J.A.15
Liras, S.16
-
15
-
-
0023853769
-
Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs
-
Farde, L.; Wiesel, F.; Halldin, C.; Sedval, G. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs Arch. Gen. Psychiatry 1988, 45, 71-76 (Pubitemid 18018572)
-
(1988)
Archives of General Psychiatry
, vol.45
, Issue.1
, pp. 71-76
-
-
Farde, L.1
Wiesel, F.-A.2
Halldin, C.3
Sedvall, G.4
-
16
-
-
64149113053
-
Phosphodiesterase 10A inhibition modulates the sensitivity of the mesolimbic dapaminergic system to D-amphetamine: Involvement of the D1-regulated feedback control of midbrain dopamine neurons
-
Sotty, F.; Montezinho, L.; Steiniger-Brach, B.; Nielson, J. Phosphodiesterase 10A inhibition modulates the sensitivity of the mesolimbic dapaminergic system to D-amphetamine: involvement of the D1-regulated feedback control of midbrain dopamine neurons J. Neurochem. 2009, 109, 766-775
-
(2009)
J. Neurochem.
, vol.109
, pp. 766-775
-
-
Sotty, F.1
Montezinho, L.2
Steiniger-Brach, B.3
Nielson, J.4
-
17
-
-
12344326514
-
Treatments for schizophrenia: A critical review of pharmacology and mechanisms of action of antipsychotic drugs
-
DOI 10.1038/sj.mp.4001556
-
Miyamoto, S.; Duncan, G. E.; Marx, C. E.; Lieberman, J. A. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs Mol. Psychiatry 2005, 10, 79-104 (Pubitemid 40139590)
-
(2005)
Molecular Psychiatry
, vol.10
, Issue.1
, pp. 79-104
-
-
Miyamoto, S.1
Duncan, G.E.2
Marx, C.E.3
Lieberman, J.A.4
-
18
-
-
77649092400
-
A possible role for the striatum in the pathogenesis of the cognitive symptoms of schizophrenia
-
Simpson, E. H.; Kellendonk, C.; Kandel, E. A possible role for the striatum in the pathogenesis of the cognitive symptoms of schizophrenia Neuron 2010, 65, 585-596
-
(2010)
Neuron
, vol.65
, pp. 585-596
-
-
Simpson, E.H.1
Kellendonk, C.2
Kandel, E.3
-
19
-
-
33847022578
-
The potential therapeutic use of phosphodiesterase 10 inhibitors
-
Kehler, A. R.; Greve, D. R. The potential therapeutic use of phosphodiesterase 10 inhibitors Expert Opin. Ther. Pat. 2007, 17, 147-158
-
(2007)
Expert Opin. Ther. Pat.
, vol.17
, pp. 147-158
-
-
Kehler, A.R.1
Greve, D.R.2
-
20
-
-
33846975147
-
Role of phosphodiesterases in neurological and psychiatric disease
-
DOI 10.1016/j.coph.2006.08.014, PII S1471489206001950, Neurosciences
-
Hebb, A. L.; Robertson, H. A. Role of phosphodiesterases in neurological and psychiatric disease Curr. Opin. Pharmacol. 2007, 7, 86-92 (Pubitemid 46242039)
-
(2007)
Current Opinion in Pharmacology
, vol.7
, Issue.1
, pp. 86-92
-
-
Hebb, A.L.1
Robertson, H.A.2
-
21
-
-
42449099422
-
Preclinical characterization of selective phosphodiesterase 10A inhibitors: A new therapeutic approach to the treatment of schizophrenia
-
DOI 10.1124/jpet.107.132910
-
Schmidt, C. J.; Chapin, D. S.; Cianfrogna, J.; Corman, M. L.; Hajos, M.; Harms, J. F.; Hoffman, W. E.; Lebel, L. A.; McCarthy, S. A.; Nelson, F. R.; Proulx-LaFrance, C.; Majchrzak, M. J.; Ramirez, A. D.; Schmidt, K.; Seymour, P. A.; Siuciak, J. A.; Tingley, F. D., III; Williams, R. D.; Verhoest, P. R.; Menniti, F. S. Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia J. Pharmacol. Exp. Ther. 2008, 325, 681-690 (Pubitemid 351574819)
-
(2008)
Journal of Pharmacology and Experimental Therapeutics
, vol.325
, Issue.2
, pp. 681-690
-
-
Schmidt, C.J.1
Chapin, D.S.2
Cianfrogna, J.3
Corman, M.L.4
Hajos, M.5
Harms, J.F.6
Hoffman, W.E.7
Lebel, L.A.8
McCarthy, S.A.9
Nelson, F.R.10
Proulx-LaFrance, C.11
Majchrzak, M.J.12
Ramirez, A.D.13
Schmidt, K.14
Seymour, P.A.15
Siuciak, J.A.16
Tingley III, F.D.17
Williams, R.D.18
Verhoest, P.R.19
Menniti, F.S.20
more..
-
22
-
-
33746629480
-
Phosphodiesterases in the CNS: Targets for drug development
-
Menniti, F. S.; Faraci, W. S.; Schmidt, C. J. Phosphodiesterases in the CNS: targets for drug development Nat. Rev. Drug Discovery 2006, 5, 661-670
-
(2006)
Nat. Rev. Drug Discovery
, vol.5
, pp. 661-670
-
-
Menniti, F.S.1
Faraci, W.S.2
Schmidt, C.J.3
-
23
-
-
35148895860
-
PDE inhibitors in psychiatry - future options for dementia, depression and schizophrenia?
-
DOI 10.1016/j.drudis.2007.07.023, PII S1359644607003066
-
Halene, T. B.; Siegel, S. J. PDE Inhibitors in psychiatry-future options for dementia, depression and schizophrenia? Drug Discovery Today 2007, 12, 870-878 (Pubitemid 47539966)
-
(2007)
Drug Discovery Today
, vol.12
, Issue.19-20
, pp. 870-878
-
-
Halene, T.B.1
Siegel, S.J.2
-
24
-
-
33748686575
-
Cyclic nucleotide phosphodiesterases: Molecular regulation to clinical use
-
DOI 10.1124/pr.58.3.5
-
Bender, A. T.; Beavo, J. A. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use Pharmacol. Rev. 2006, 58, 488-520 (Pubitemid 44394910)
-
(2006)
Pharmacological Reviews
, vol.58
, Issue.3
, pp. 488-520
-
-
Bender, A.T.1
Beavo, J.A.2
-
25
-
-
78650779872
-
Chronic suppression of phosphodiesterase 10A alters striatal expression of genes responsible for neurotransmitter synthesis, neurotransmission, and signaling pathways implicated in Huntingont's disease
-
Kleiman, R. J.; Kimmel, L. H.; Bove, S. E.; Lanz, T. A.; Harms, J. F.; Romegialli, A.; Miller, K. S.; Willis, A.; des Etages, S.; Kuhn, M.; Schmidt, C. J. Chronic suppression of phosphodiesterase 10A alters striatal expression of genes responsible for neurotransmitter synthesis, neurotransmission, and signaling pathways implicated in Huntingont's disease J. Pharmacol. Exp. Ther. 2011, 336, 64-76
-
(2011)
J. Pharmacol. Exp. Ther.
, vol.336
, pp. 64-76
-
-
Kleiman, R.J.1
Kimmel, L.H.2
Bove, S.E.3
Lanz, T.A.4
Harms, J.F.5
Romegialli, A.6
Miller, K.S.7
Willis, A.8
Des Etages, S.9
Kuhn, M.10
Schmidt, C.J.11
-
26
-
-
72049086425
-
Alterations in gene regulations following inhibition of the striatum-enriched phosphodiesterase, PDE10A
-
Strick, C. A.; James, L. C.; Fox, C. B.; Seeger, T. F.; Menniti, F. S.; Schmidt, C. J. Alterations in gene regulations following inhibition of the striatum-enriched phosphodiesterase, PDE10A Neuropharmacology 2010, 58, 444-451
-
(2010)
Neuropharmacology
, vol.58
, pp. 444-451
-
-
Strick, C.A.1
James, L.C.2
Fox, C.B.3
Seeger, T.F.4
Menniti, F.S.5
Schmidt, C.J.6
-
27
-
-
33646180173
-
Comparison of rat dopamine D2 receptor occupancy for a series of antipsychotic drugs measuredusing radiolabeled or nonlabeled raclopride
-
Barth, V.; Chernet, E.; Martin, L.; Need, A.; Rash, K.; Morin, M.; Phebus, L. A. Comparison of rat dopamine D2 receptor occupancy for a series of antipsychotic drugs measuredusing radiolabeled or nonlabeled raclopride Life Sci. 2006, 78, 3007-3012
-
(2006)
Life Sci.
, vol.78
, pp. 3007-3012
-
-
Barth, V.1
Chernet, E.2
Martin, L.3
Need, A.4
Rash, K.5
Morin, M.6
Phebus, L.A.7
-
28
-
-
35348996615
-
In vivo rat brain opioid receptor binding of LY255582 assessed with a novel method using LC/MS/MS and the administration of three tracers simultaneously
-
DOI 10.1016/j.lfs.2007.09.005, PII S0024320507006662
-
Need, A. B.; McKinzie, J, H.; Mitch, C. H.; Statnick, M. A.; Phebus, L. A. In vivo rat brain opioid receptor binding of LY255582 assessed with a novel method using LC/MS/MS and the administration of three tracers simultaneously Life Sci. 2007, 81, 1389-1396 (Pubitemid 47603187)
-
(2007)
Life Sciences
, vol.81
, Issue.17-18
, pp. 1389-1396
-
-
Need, A.B.1
McKinzie, J.H.2
Mitch, C.H.3
Statnick, M.A.4
Phebus, L.A.5
-
29
-
-
27744530843
-
Use of LC/MS to assess brain tracer distribution in preclinical, in vivo receptor occupancy studies: Dopamine D2, serotonin 2A and NK-1 receptors as examples
-
DOI 10.1016/j.lfs.2005.04.075, PII S0024320505007915
-
Chernet, E.; Martin, L. J.; Li, D.; Need, A. B.; Barth, V. N.; Rash, K. S.; Phebus, L. A. Use of LC/MS to assess brain tracer distribution in preclinical, in vivo receptor occupancy studies: dopamine D2, serotonin 2A and NK-1 receptors as examples Life Sci. 2005, 78, 340-346 (Pubitemid 41599770)
-
(2005)
Life Sciences
, vol.78
, Issue.4
, pp. 340-346
-
-
Chernet, E.1
Martin, L.J.2
Li, D.3
Need, A.B.4
Barth, V.N.5
Rash, K.S.6
Phebus, L.A.7
-
31
-
-
84857922134
-
-
WO 2007098169
-
Arrington, M. P.; Liu, R.; Hopper, A. T.; Conticello, R. D.; Nguyen, T. M.; Gauss, C. M.; Burli, R.; Hitchcock, S. A.; Hu, E.; Kunz, R. Cinnoline Derivatives as Phosphodiesterase 10 Inhibitors, Their Preparation, Pharmaceutical Compositions, and Use in Therapy. WO 2007098169, 2007.
-
(2007)
Cinnoline Derivatives As Phosphodiesterase 10 Inhibitors, Their Preparation, Pharmaceutical Compositions, and Use in Therapy
-
-
Arrington, M.P.1
Liu, R.2
Hopper, A.T.3
Conticello, R.D.4
Nguyen, T.M.5
Gauss, C.M.6
Burli, R.7
Hitchcock, S.A.8
Hu, E.9
Kunz, R.10
-
32
-
-
0036386982
-
Measuring drug-related receptor occupancy with positron emission tomography
-
Passchier, J.; Gee, A.; Willemsen, A.; Vaalburg, W.; van Waarde, A. Measuring drug-related receptor occupancy with positron emission tomography Methods 2002, 27, 278-286
-
(2002)
Methods
, vol.27
, pp. 278-286
-
-
Passchier, J.1
Gee, A.2
Willemsen, A.3
Vaalburg, W.4
Van Waarde, A.5
-
33
-
-
0344121285
-
Predicting the success of a radiopharmaceutical for in vivo imaging of central nervous system neuroreceptor systems
-
DOI 10.1016/j.mibio.2003.09.011, PII S1536163203001690
-
Wong, D. F.; Pomper, M. G. Predicting the success of a radiopharmaceutical for in vivo imaging of central nervous system neuroreceptor systems Mol. Imaging Biol. 2003, 5, 350-362 (Pubitemid 37489826)
-
(2003)
Molecular Imaging and Biology
, vol.5
, Issue.6
, pp. 350-362
-
-
Wong, D.F.1
Pomper, M.G.2
-
34
-
-
2542490139
-
PET tracer and radiochemistry
-
Schlyer, D. PET tracer and radiochemistry Ann. Acad. Med., Singapore 2004, 33, 146-154
-
(2004)
Ann. Acad. Med., Singapore
, vol.33
, pp. 146-154
-
-
Schlyer, D.1
-
35
-
-
0015861774
-
Relationshiop between the inhibition constant (K1) and the concentration of inhibitor which causes 50 percent inhibition (I50) of an enzymatic reaction
-
Cheng, Y; Prusoff, W. H. Relationshiop between the inhibition constant (K1) and the concentration of inhibitor which causes 50 percent inhibition (I50) of an enzymatic reaction Biochem. Pharmacol. 1973, 22, 3099-3108
-
(1973)
Biochem. Pharmacol.
, vol.22
, pp. 3099-3108
-
-
Cheng, Y.1
Prusoff, W.H.2
-
36
-
-
79851490485
-
18F-JNJ41510417 as a radioligand for PET imaging of phosphodiesterase-10A in the brain
-
18F-JNJ41510417 as a radioligand for PET imaging of phosphodiesterase-10A in the brain J. Nucl. Med. 2010, 51, 1584-1591
-
(2010)
J. Nucl. Med.
, vol.51
, pp. 1584-1591
-
-
Celen, S.1
Koole, M.2
De Angelis, M.3
Sannen, I.4
Chitneni, S.K.5
Alcázar, J.6
Dedeurwaerdere, S.7
Moechars, D.8
Schmidt, M.9
Verbruggen, A.10
Langlois, X.11
Van Laere, K.12
Andrés, J.I.13
Bormans, G.14
-
37
-
-
80051897157
-
Synthesis, in vivo occupancy, and radiolabeling of potent phosphodiesterase subtype-10 inhibitors as candidates for positron emission tomography imaging
-
Andrés, J.-I.; De Angelis, M.; Alcázar, J.; Iturrino, L.; Langlois, X.; Dedeurwaerdere, S.; Lenaerts, I.; Vanhoof, G.; Celen, S.; Bormans, G. Synthesis, in vivo occupancy, and radiolabeling of potent phosphodiesterase subtype-10 inhibitors as candidates for positron emission tomography imaging J. Med. Chem. 2011, 54, 5820-5853
-
(2011)
J. Med. Chem.
, vol.54
, pp. 5820-5853
-
-
Andrés, J.-I.1
De Angelis, M.2
Alcázar, J.3
Iturrino, L.4
Langlois, X.5
Dedeurwaerdere, S.6
Lenaerts, I.7
Vanhoof, G.8
Celen, S.9
Bormans, G.10
-
38
-
-
0028825399
-
Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A
-
Schinkel, A. H.; Wagenaar, E.; van Deemter, L.; Mol, C. A.; Borst, P. Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A J. Clin. Invest. 1995, 96, 1698-1705
-
(1995)
J. Clin. Invest.
, vol.96
, pp. 1698-1705
-
-
Schinkel, A.H.1
Wagenaar, E.2
Van Deemter, L.3
Mol, C.A.4
Borst, P.5
-
39
-
-
31144460354
-
Analyzing a kinetic titration series using affinity biosensors
-
DOI 10.1016/j.ab.2005.09.034, PII S0003269705006986
-
Karlsson, R.; Katsamba, P. S.; Nordin, H.; Pol, E.; Myszka, D. G. Analyzing a kinetic titration series using affinity biosensors Anal. Biochem. 2006, 349, 136-147 (Pubitemid 43129567)
-
(2006)
Analytical Biochemistry
, vol.349
, Issue.1
, pp. 136-147
-
-
Karlsson, R.1
Katsamba, P.S.2
Nordin, H.3
Pol, E.4
Myszka, D.G.5
-
40
-
-
0034783501
-
2 receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects
-
DOI 10.1016/S0893-133X(01)00261-5, PII S0893133X01002615
-
Wadenberg, M.; Soliman, A.; VanderSpek, S. C.; Kapur, S. Dopamine D2 receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects Neuropsychopharmacology 2001, 25, 633-641 (Pubitemid 32995945)
-
(2001)
Neuropsychopharmacology
, vol.25
, Issue.5
, pp. 633-641
-
-
Wadenberg, M.-L.G.1
Soliman, A.2
VanderSpek, S.C.3
Kapur, S.4
|